Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cannabis Use Induces Distinctive Proteomic Alterations in Olfactory Neuroepithelial Cells of Schizophrenia Patients

  • Barrera-Conde, Marta|||0000-0002-0106-0000
  • Ausin, Karina|||0000-0003-4914-9466
  • Lachén-Montes, Mercedes
  • Fernández-Irigoyen, Joaquín|||0000-0001-5072-4099
  • Galindo, Liliana|||0000-0002-2396-4772
  • Cuenca-Royo, Aida|||0000-0001-8551-5457
  • Fernández-Avilés, Cristina|||0000-0002-1029-9216
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Santamaría, Enrique
  • Robledo, Patricia
A close epidemiological link has been reported between cannabis use and schizophrenia (SCZ). However, biochemical markers in living humans related to the impact of cannabis in this disease are still missing. Olfactory neuroepithelium (ON) cells express neural features and offer a unique advantage to study biomarkers of psychiatric diseases. The aim of our study was to find exclusively deregulated proteins in ON cells of SCZ patients with and without a history of cannabis use. Thus, we compared the proteomic profiles of SCZ non-cannabis users (SCZ/nc) and SCZ cannabis users (SCZ/c) with control subjects non-cannabis users (C/nc) and control cannabis users (C/c). The results revealed that the main cascades affected in SCZ/nc were cell cycle, DNA replication, signal transduction and protein localization. Conversely, cannabis use in SCZ patients induced specific alterations in metabolism of RNA and metabolism of proteins. The levels of targeted proteins in each population were then correlated with cognitive performance and clinical scores. In SCZ/c, the expression levels of 2 proteins involved in the metabolism of RNA (MTREX and ZNF326) correlated with several cognitive markers and clinical signs. Moreover, use duration of cannabis negatively correlated with ZNF326 expression. These findings indicate that RNA-related proteins might be relevant to understand the influence of cannabis use on SCZ.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Reversible Photocontrol of Dopaminergic Transmission in Wild-Type Animals

  • Matera, Carlo|||0000-0001-6939-3859
  • Calvé, Pablo
  • Casadó-Anguera, Verònica|||0000-0001-8532-2954
  • Sortino, Rosalba|||0000-0002-8854-6782
  • Gomila, Alexandre|||0000-0003-0867-6171
  • Moreno, Estefanía|||0000-0002-2491-5753
  • Gener, Thomas Adrien|||0000-0001-9209-9228
  • Delgado-Sallent, Cristina|||0000-0002-2202-1043
  • Nebot, Pau
  • Costazza, Davide|||0000-0002-7876-0291
  • Conde Berriozabal, Sara|||0000-0002-3712-8046
  • Masana, Mercè|||0000-0003-1392-4774
  • Hernando, Jordi|||0000-0002-1126-4138
  • Casadó, Vicent|||0000-0002-1764-3825
  • Puig Velasco, Maria Victoria|||0000-0002-1490-4153
  • Gorostiza, Pau|||0000-0002-7268-5577
Understanding the dopaminergic system is a priority in neurobiology and neuropharmacology. Dopamine receptors are involved in the modulation of fundamental physiological functions, and dysregulation of dopaminergic transmission is associated with major neurological disorders. However, the available tools to dissect the endogenous dopaminergic circuits have limited specificity, reversibility, resolution, or require genetic manipulation. Here, we introduce azodopa, a novel photoswitchable ligand that enables reversible spatiotemporal control of dopaminergic transmission. We demonstrate that azodopa activates D1-like receptors in vitro in a light-dependent manner. Moreover, it enables reversibly photocontrolling zebrafish motility on a timescale of seconds and allows separating the retinal component of dopaminergic neurotransmission. Azodopa increases the overall neural activity in the cortex of anesthetized mice and displays illumination-dependent activity in individual cells. Azodopa is the first photoswitchable dopamine agonist with demonstrated efficacy in wild-type animals and opens the way to remotely controlling dopaminergic neurotransmission for fundamental and therapeutic purposes.